

## Quarterly Report for the Period Ended 30 June 2014

**Melbourne, Australia, 31 July 2014** - Antisense Therapeutics Limited ("ASX:ANP" or "the Company") is pleased to release its Quarterly Report for the three months ended 30 June 2014. Key highlights include:

- ATL1102 for Multiple Sclerosis (MS) Toxicology Study results support plans for further development
- Addition of a new US Patent for ATL1102 for MS extends strong IP position
- \$1.0m non-dilutive funding facility in place ahead of R&D Tax incentive refund
- ATL1103 Phase II Acromegaly trial progresses

Cash at bank as at 30 June 2014 was \$1.3 million. This is boosted by a \$1.0 million non-dilutive funding facility with Macquarie Bank Limited to access capital on an on-going draw down basis ahead of anticipated receipt of the Company's R&D Tax incentive refund of approximately \$1.2 million which is expected by year end (2014). As at the date of this announcement, \$0.95 million is available for draw down net of costs. Proceeds from the R&D Tax incentive refund would be used to repay the funding facility.

During the quarter Antisense Therapeutics has been making solid progress in the clinic with its pipeline of products targeting significant unmet medical needs.

In April, ANP released new animal toxicology results on ATL1102 which provide the opportunity for the Company to discuss plans for the further development of ATL1102 with the US Food and Drug Administration (FDA). Subsequently to the end of the quarter, ANP submitted its formal request for a pre-IND meeting for the FDA's assessment of ANP's design for a Phase IIb clinical trial in MS patients.

The Company's patent portfolio has also been broadened during the quarter with the addition of a new patent issued in the US for the use of ATL1102 in MS. This adds further commercial value to ATL1102 for MS. The new patent strengthens the IP position and forms a part of the Company's extensive portfolio of IP protecting ATL1102 and its uses in MS.

Significantly, ANP also had positive progress with the development of its lead drug ATL1103 targeting the growth disorder acromegaly and subsequent to the period end, the Company has reported the completion of dosing of all patients in the Phase II trial (as announced on 29 July 2014) with primary efficacy results expected by the end of August 2014. There were no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103 from all 26 patients who had completed dosing in the Phase II trial.

### Contact Information:

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director: Mark Diamond +61 (3) 9827 8999

Investor Relations: Annabel Murphy, Buchan Consulting +61 (2) 9237 2800

# Appendix 4C – 4<sup>th</sup> Quarter

## Quarterly Report for Entities Admitted on the Basis of Commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

**Name of Entity:**

Antisense Therapeutics Limited

**ABN:**

41 095 060 745

**Quarter Ended ('Current Quarter')**

30<sup>th</sup> June 2014

### Consolidated Statement of Cash Flows

<b>Cash Flows Related to Operating Activities</b>		<b>Current Quarter \$A'000</b>	<b>Year-to-Date (12 months) \$A'000</b>
1.1	Receipts from customers	-	-
1.2	Payments for:		
	(a) staff costs (including R&D staffing costs)	(249)	(990)
	(b) advertising/marketing/investor relations	(31)	(166)
	(c) research and development (excluding R&D staffing costs)	(858)	(2,171)
	(d) leased assets	-	-
	(e) other working capital	(189)	(892)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	16	85
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other (R&D Tax Concession refund )	-	974
<b>Net Operating Cash Flows</b>		<b>(1,311)</b>	<b>(3,160)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly Report for Entities**  
**Admitted on the Basis of Commitments**

		Current Quarter \$A'000	Year-to-Date (12 months) \$A'000
1.8	<b>Net Operating Cash Flows (carried forward)</b>	<b>(1,311)</b>	<b>(3,160)</b>
<b><u>Cash Flows Related to Investing Activities</u></b>			
1.9	Payment for acquisition of:		
	(a) businesses (item)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	-	-
<b>Net Investing Cash Flows</b>		<b>-</b>	<b>-</b>
<b>1.14</b>	<b>Total Operating and Investing Cash Flows</b>	<b>(1,311)</b>	<b>(3,160)</b>
<b><u>Cash Flows Related to Financing Activities</u></b>			
1.15	Proceeds from issues of shares, options, etc.	-	551
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	50	50
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (Capital raising costs/ Borrowing costs)	(73)	(136)
<b>Net Financing Cash Flows</b>		<b>(23)</b>	<b>465</b>
<b>Net Increase / (Decrease) in Cash Held</b>		<b>(1,334)</b>	<b>(2,695)</b>
1.21	Cash at beginning of quarter/year to date	<b>2,668</b>	<b>4,000</b>
1.22	Exchange rate adjustments to item 1.21	-	29
<b>1.23</b>	<b>Cash at End of Quarter *</b>	<b>1,334</b>	<b>1,334</b>

\* As announced on 2<sup>nd</sup> June 2014 the Company has entered into a funding facility with Macquarie Bank Limited to access capital on an ongoing draw down basis ahead of the receipt of its R&D Tax incentive refund. This non-dilutive (non-equity related) secured facility has a limit of A\$1.0 million and is due for repayment in full by 30 November 2014 from the proceeds of the Company's anticipated 2014 R&D Tax incentive refund of approx. A\$1.2 million. As at the date of this announcement, \$0.95 million is available for draw down net of costs.

**Payments to Directors of the Entity and Associates of the Directors**

**Payments to Related Entities of the Entity and Associates of the Related Entities**

		<b>Current Quarter \$A'000</b>
1.24	Aggregate amount of payments to the parties included in item 1.2	134
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	Item 1.24 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements).	

**Non-Cash Financing and Investing Activities**

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

**Financing Facilities Available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

		<b>Amount Available \$A'000</b>	<b>Amount Used \$A'000</b>
3.1	Loan facilities	1000	50
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

## Reconciliation of Cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current Quarter \$A'000	Previous Quarter \$A'000
4.1 Cash on hand and at bank	129	268
4.2 Deposits at call	1,205	2,400
4.3 Bank overdraft	-	-
4.4 Other - Bank Guarantee / Trust	-	-
<b>Total: Cash at End of Quarter (item 1.23)</b>	<b>1,334</b>	<b>2,668</b>

## Acquisitions and Disposals of Business Entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	-	-
5.2 Place of incorporation or registration	-	-
5.3 Consideration for acquisition or disposal	-	-
5.4 Total net assets	-	-
5.5 Nature of business	-	-

## Compliance statement

- This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- This statement does give a true and fair view of the matters disclosed.

Sign Here: \_\_\_\_\_



Print Name: **Phillip Hains**  
Company Secretary

Date: Thursday 31<sup>th</sup> July 2014



The CFO Solution

31 July 2014

+ See chapter 19 for defined terms.

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.